Clinical Development

In the evolving landscape of drug development and life sciences investing, driving clinical innovation has long been an industry challenge. The high cost and complexity of clinical trial design, execution, and development (spanning novel drug candidates to med‑tech solutions) have historically concentrated activity among a small number of large pharmaceutical companies. These firms benefit from substantial resources, scale, and established clinical networks, factors that can create significant barriers to entry for emerging participants.

​

LGC addresses these structural challenges in clinical development by providing portfolio companies with access to a specialised clinical network designed to reduce execution risk and accelerate value creation. Through this network, companies benefit from optimised regulatory strategies, more efficient trial design and protocol development, improved endpoint selection, faster patient recruitment, and enhanced data management, helping to unlock embedded value and level the playing field against larger incumbents.